Extracellular Vesicles in Cardiovascular Disease: Intercellular Signaling, Liquid Biopsy Biomarkers, and Therapeutic Translation
- 14 August 2026
- journal article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (5)
Abstract
Cardiovascular diseases remain the leading global cause of mortality, highlighting the need for improved early detection and targeted interventions. Extracellular vesicles (EVs) are nano-sized, bilipid-layered particles released by all cell types that carry RNAs, proteins, lipids, and metabolites reflective of their parent cells. They mediate intercellular communication by transferring cargo that alters recipient cell transcriptomic and proteomic states, and this property may be leveraged for therapeutic delivery. This review provides a comprehensive, cardiovascular disease–focused synthesis of EV biology with emphasis on what is clinically actionable and mechanistically novel. The review describes EV biogenesis and their multiomic cargo composition, followed by tissue-resolved and cell type–resolved EV signaling across cell types relevant to cardiovascular disease. A dedicated section addresses EV-mediated interorgan crosstalk across the heart-kidney, heart-liver, brain-heart, and adipose-heart axes as a systems-level framework for cardiometabolic disease. We next turn to translational applications, describing EV cargo composition under pathological conditions with implications for disease-related signaling and the potential for biomarker development. For liquid biopsy applications, the review introduces a 3-tier evidence framework classifying circulating EV biomarkers by clinical validation status, supported by a practical preanalytical checklist for cardiovascular plasma studies. Engineered, stem cell–derived, and RNA-loaded EV therapeutic modalities are evaluated, and active clinical trials are catalogued along with key challenges in cargo loading, biodistribution, immunogenicity, and regulatory standardization. We conclude with a structured future directions and perspectives section identifying the most tractable open questions required to advance EVs from discovery to cardiovascular clinical practice.Keywords
This publication has 364 references indexed in Scilit:
- Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular VesiclesAdvanced Science, 2025
- Microneedle Patch Loaded with Exosomes Containing MicroRNA‐29b Prevents Cardiac Fibrosis after Myocardial InfarctionAdvanced Healthcare Materials, 2023
- A pH/H2O2/MMP9 Time‐Response Gel System with Sparchigh Tregs Derived Extracellular Vesicles Promote Recovery After Acute Myocardial InfarctionAdvanced Healthcare Materials, 2022
- Cardiac troponin T in extracellular vesicles as a novel biomarker in human cardiovascular diseaseClinical and Translational Medicine, 2022
- Bioengineering Extracellular Vesicles for the Treatment of Cardiovascular DiseasesAdvanced Biology, 2022
- Extracellular vesicle‐packaged mitochondrial disturbing miRNA exacerbates cardiac injury during acute myocardial infarctionClinical and Translational Medicine, 2022
- Exosomal LINC01005 derived from oxidized low‐density lipoprotein‐treated endothelial cells regulates vascular smooth muscle cell phenotypic switchBioFactors, 2020
- Cardiomyocyte-Derived Exosomal MicroRNA-92A Mediates Post-Ischemic Myofibroblast Activation Both in Vitro and Ex VivoESC Heart Failure, 2020
- Transcoronary Concentration Gradients of Circulating microRNAs in Heart FailureEuropean Journal of Heart Failure, 2018
- Subdiffraction‐Resolution Fluorescence Imaging with Conventional Fluorescent ProbesAngewandte Chemie International Edition, 2008